Jazz Pharmaceuticals Ireland Clinical Trials

Company details

Status: Public
HQ: Waterloo Exchange, Waterloo Road, Dublin, 4, IE
Founded: 2003
Employees: 3,631
Programs: 208
Drugs: 91
Patents: 89

Official website ↗ All projects Drug pipeline Patents News & analysis

Recent trial activity

8 updates

Latest clinical program signals indexed for Jazz Pharmaceuticals Ireland.

Trial registry

255 studies

2023-508135-30-00
ZWI-ZW25-202

Phase 2 active small_molecule

Breast cancer patients including those with locally advanced (unresectable) or metastatic HER2-positive, HR-positive breast cancer

CTIS ↗
2023-508219-21-00
JZP598-302

Phase 3 active small_molecule

BTC - Biliary Tract Cancer

CTIS ↗
2023-508960-31-00
JZP598-303

Phase 3 active small_molecule

Metastatic HER2-positive breast cancer

CTIS ↗
2023-510319-20-00
ZWI-ZW25-301

Phase 3 active small_molecule

Gastroesophageal Adenocarcinoma (GEA)

CTIS ↗
2024-516551-41-00
JZP598

Phase 2 active small_molecule

Patients with HER2-expressing solid tumors

CTIS ↗
2025-523204-68-00
EmpowHER 208

Phase 2 active small_molecule

HER2-positive breast cancer

CTIS ↗
NCT00003966
Defibrotide

Phase 3 completed small_molecule

Veno-occlusive Disease

CT.gov ↗
NCT00066170
Xyrem

Phase 3 completed small_molecule

Narcolepsy

CT.gov ↗
NCT00086281
Xyrem (X)

Approved completed small_molecule

Obstructive Sleep Apnea Syndrome

CT.gov ↗
NCT00087555
Xyrem (sodium oxybate) oral solution

Phase 2 completed small_molecule

Fibromyalgia

CT.gov ↗
NCT00097708
experimental anti-anxiety drug

Phase 3 completed small_molecule

Anxiety Disorder

CT.gov ↗
NCT00106860
a benzodiazepine drug

Phase 3 completed small_molecule

Anxiety Disorder

CT.gov ↗
NCT00132873
Xyrem (sodium oxybate) oral solution

Phase 3 completed small_molecule

Narcolepsy

CT.gov ↗
NCT00272948
Defibrotide

Phase 3 completed small_molecule

Hepatic Veno-Occlusive Disease

CT.gov ↗
NCT00358501
Defibrotide

Phase 3 completed small_molecule

Severe Hepatic Veno-Occlusive Disease

CT.gov ↗
NCT00361842
CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection

Phase 2 completed small_molecule

Colorectal Neoplasms

CT.gov ↗
NCT00371137
Xyrem®

Phase 3 completed small_molecule

Fibromyalgia

CT.gov ↗
NCT00389428
CPX-351 (Cytarabine:Daunorubicin) Liposome Injection

Phase 1 completed small_molecule

Hematologic Neoplasms

CT.gov ↗
NCT00423605
Xyrem®

Phase 3 completed small_molecule

Fibromyalgia

CT.gov ↗
NCT00423813
placebo

Phase 3 completed small_molecule

Fibromyalgia

CT.gov ↗
NCT00457951
Open-Label

Phase 2 terminated small_molecule

Chronic Obstructive Pulmonary Disease

CT.gov ↗
NCT00498485
Placebo

Approved terminated small_molecule

Chronic Fatigue Syndrome

CT.gov ↗
NCT00506974
sodium oxybate

Approved completed small_molecule

Sleep

CT.gov ↗
NCT00514995
Sodium Oxybate

Phase 3 completed small_molecule

Binge Eating Disorder

CT.gov ↗
NCT00594256
Sodium Oxybate

Phase 2 completed small_molecule

Schizophrenia

CT.gov ↗
NCT00594945
Clonazepam

Phase 2 completed small_molecule

Epilepsy

CT.gov ↗
NCT00598078
Sodium Oxybate

Phase 2 completed small_molecule

Essential Tremor

CT.gov ↗
NCT00628498
Defibrotide

Phase 3 completed small_molecule

Hepatic Veno-Occlusive Disease

CT.gov ↗
NCT00641186
sodium oxybate

Phase 2 completed small_molecule

Parkinson Disease

CT.gov ↗
NCT00670696
Rapydan

Approved terminated small_molecule

Healthy

CT.gov ↗
NCT00674609
Placebo

Phase 3 completed small_molecule

Palliative Care

CT.gov ↗
NCT00675948
Sativex

Phase 3 completed small_molecule

Pain

CT.gov ↗
NCT00678795
Sativex®

Phase 3 completed small_molecule

Detrusor Overactivity

CT.gov ↗
NCT00681538
Sativex®

Phase 3 completed small_molecule

Spasticity

CT.gov ↗
NCT00693602
Erwinase

Phase 1 completed small_molecule

Acute Lymphoblastic Leukemia

CT.gov ↗
NCT00702468
Sativex®

Phase 3 completed small_molecule

Spasticity

CT.gov ↗
NCT00710424
Sativex

Phase 3 completed small_molecule

Pain

CT.gov ↗
NCT00710554
Sativex

Phase 3 completed small_molecule

Pain

CT.gov ↗
NCT00711646
Sativex®

Phase 3 completed small_molecule

Spasticity

CT.gov ↗
NCT00711880
Sativex

Phase 3 completed small_molecule

Pain

CT.gov ↗
NCT00713323
Sativex

Phase 3 completed small_molecule

Pain

CT.gov ↗
NCT00713817
Sativex

Phase 3 completed small_molecule

Pain

CT.gov ↗
NCT00780182
CMX001

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT00788892
CPX-351

Phase 2 completed small_molecule

Acute Myeloid Leukemia

CT.gov ↗
NCT00793598
Placebo

Phase 2 completed small_molecule

Viruria

CT.gov ↗
NCT00803023
Sodium Oxybate

Phase 3 completed small_molecule

Fibromyalgia

CT.gov ↗
NCT00822094
CPX-351

Phase 2 completed small_molecule

Acute Myeloid Leukemia

CT.gov ↗
NCT00875693
CPX-351

Phase 1 completed small_molecule

Acute Myelogenous Leukemia

CT.gov ↗
NCT00901732
Caphosol

Phase 2 active other

Oral Mucositis

CT.gov ↗
NCT00931164
Sodium Oxybate

Phase 2 completed small_molecule

Alternating Hemiplegia of Childhood

CT.gov ↗
NCT00942305
Brincidofovir

Phase 2 completed small_molecule

Cytomegalovirus Infection

CT.gov ↗
NCT01080820
CMX157

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT01143181
Brincidofovir

Phase 3 completed small_molecule

Double-stranded DNA Virus

CT.gov ↗
NCT01161641
ODSH at 0.125 mg/kg/h

Phase 1 terminated small_molecule

Protein Losing Enteropathy

CT.gov ↗
NCT01217112
GWP42003

Phase 2 completed small_molecule

Dyslipidemias

CT.gov ↗
NCT01241344
Brincidofovir

Phase 2 completed small_molecule

Adenovirus Disease

CT.gov ↗
NCT01265810
supersaturated calcium-phosphate

Phase 3 completed other

Oral Complaints

CT.gov ↗
NCT01322139
Placebo spray and oral moxifloxacin placebo

Phase 1 completed small_molecule

Effects of Sativex on ECG

CT.gov ↗
NCT01322464
Sativex

Phase 1 completed small_molecule

Food Effect

CT.gov ↗
NCT01323465
Sativex and rifampicin

Phase 1 completed small_molecule

Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4

CT.gov ↗
NCT01323569
Sativex

Phase 1 completed small_molecule

Evaluation of Abuse Potential of Sativex

CT.gov ↗
NCT01337089
Nabiximols

Phase 3 completed small_molecule

Pain

CT.gov ↗
NCT01361607
Nabiximols

Phase 3 completed small_molecule

Pain

CT.gov ↗
NCT01401140
St Thomas

Phase 3 completed small_molecule

Coronary Artery Stenosis

CT.gov ↗
NCT01424566
Nabiximols

Phase 3 completed small_molecule

Pain

CT.gov ↗
NCT01426295
Bicarbonate de sodium

Phase 2 completed small_molecule

Hematologic Disease

CT.gov ↗
NCT01485770
ADX-N05

Phase 2 completed small_molecule

Narcolepsy

CT.gov ↗
NCT01551524
mPEG-r-crisantaspase

Phase 1 completed mab

Hematologic Malignancies

CT.gov ↗
NCT01599234
Sativex

Approved completed small_molecule

Multiple Sclerosis

CT.gov ↗
NCT01604265
Placebo

Phase 3 completed small_molecule

Multiple Sclerosis

CT.gov ↗
NCT01606137
GW-1000-02

Phase 3 completed small_molecule

Multiple Sclerosis

CT.gov ↗
NCT01606176
GW-1000-02

Phase 3 completed small_molecule

Pain

CT.gov ↗
NCT01606189
GW-1000-02

Phase 3 completed small_molecule

Pain

CT.gov ↗
NCT01606202
GW-1000-02

Phase 3 completed small_molecule

Pain

CT.gov ↗
NCT01610687
GW-1000-02

Phase 3 completed small_molecule

Multiple Sclerosis

CT.gov ↗
NCT01610700
GW-1000-02

Phase 3 completed small_molecule

Multiple Sclerosis

CT.gov ↗
NCT01610713
GW-1000-02

Phase 3 completed small_molecule

Multiple Sclerosis

CT.gov ↗
NCT01643408
asparaginase Erwinia chrysanthemi

Phase 2 completed small_molecule

Acute Lymphoblastic Leukemia

CT.gov ↗
NCT01681121
ADX-N05

Phase 2 completed small_molecule

Narcolepsy

CT.gov ↗
NCT01696084
CPX-351

Phase 3 completed small_molecule

High Risk Acute Myeloid Leukemia

CT.gov ↗
NCT01769170
Brincidofovir

Phase 3 completed small_molecule

CMV

CT.gov ↗
NCT01812603
Sativex

Phase 2 completed small_molecule

Cancer

CT.gov ↗
NCT01812616
Sativex

Phase 2 completed small_molecule

Cancer

CT.gov ↗
NCT01843634
ODSH

Phase 1 completed small_molecule

Acute Myeloid Leukemia

CT.gov ↗
NCT01886105
Sm-EDTMP

Phase 2 terminated small_molecule

Metastatic Osteosarcoma

CT.gov ↗
NCT01887301
Sativex

Phase 1 completed small_molecule

Hepatic Impairment

CT.gov ↗
NCT01898520
Sativex

Phase 3 completed small_molecule

Cerebral Palsy

CT.gov ↗
NCT01918735
Placebo

Phase 1 completed small_molecule

Epilepsy

CT.gov ↗
NCT01943682
CPX-351

Phase 2 completed small_molecule

Acute Myeloid Leukemia

CT.gov ↗
NCT01964547
Sativex

Approved completed small_molecule

Multiple Sclerosis

CT.gov ↗
NCT02006628
Placebo

Phase 2 completed small_molecule

Schizophrenia

CT.gov ↗
NCT02038699
ONC201

Phase 2 terminated small_molecule

Advanced Glioblastoma

CT.gov ↗
NCT02053272
GWP42004

Phase 2 completed small_molecule

Diabetes Mellitus, Type 2

CT.gov ↗
NCT02087306
Brincidofovir

Phase 3 completed small_molecule

Adenovirus Infection

CT.gov ↗
NCT02091206
GWP42003-P 5 mg/kg/day Dose

Phase 2 completed small_molecule

Epilepsy

CT.gov ↗
NCT02091375
GWP42003-P 20 mg/kg/Day Dose

Phase 3 completed small_molecule

Epilepsy

CT.gov ↗
NCT02150928
Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)

Phase 2 terminated small_molecule

Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)

CT.gov ↗
NCT02221869
Xyrem

Phase 3 completed small_molecule

Narcolepsy With Cataplexy

CT.gov ↗
NCT02224560
GWP42003-P

Phase 3 completed small_molecule

Epilepsy

CT.gov ↗
NCT02224690
GWP42003-P 20 mg/kg/Day Dose

Phase 3 completed small_molecule

Epilepsy

CT.gov ↗
NCT02224703
GWP42003-P

Phase 3 completed small_molecule

Epilepsy

CT.gov ↗
NCT02238925
CPX-351

Phase 2 completed small_molecule

Acute Myeloid Leukemia (AML)

CT.gov ↗
NCT02257684
pegcrisantaspase

Phase 2 terminated small_molecule

Acute Lymphoblastic Leukemia

CT.gov ↗
NCT02269579
CPX-351

Phase 2 completed small_molecule

Acute Myeloid Leukemia (AML)

CT.gov ↗
NCT02271347
CMX001

Phase 2 terminated small_molecule

Ebola Virus

CT.gov ↗
NCT02283281
Tetrahydrocannabinol

Phase 3 active small_molecule

Pain, Postoperative

CT.gov ↗
NCT02325011
Sativex® (Treatment A)

Phase 1 completed small_molecule

Healthy Subjects

CT.gov ↗
NCT02332655
Cannabidiol

Phase 2 completed small_molecule

Sturge-Weber Syndrome

CT.gov ↗
NCT02348593
JZP-110

Phase 3 completed small_molecule

Narcolepsy

CT.gov ↗
NCT02348606
JZP-110

Phase 3 completed small_molecule

Obstructive Sleep Apnea

CT.gov ↗
NCT02348619
JZP-110

Phase 3 completed small_molecule

Obstructive Sleep Apnea

CT.gov ↗
NCT02348632
JZP-110

Phase 3 completed small_molecule

Narcolepsy

CT.gov ↗
NCT02365610
GWP42006

Phase 2 completed small_molecule

Epilepsy

CT.gov ↗
NCT02369471
GWP42006

Phase 2 completed small_molecule

Epilepsy

CT.gov ↗
NCT02419469
Cytarabine

Phase 2 terminated small_molecule

Leukemia

CT.gov ↗
NCT02439957
Brincidofovir

Phase 3 terminated small_molecule

Cytomegalovirus Disease

CT.gov ↗
NCT02439970
Brincidofovir

Phase 3 terminated small_molecule

Cytomegalovirus Disease

CT.gov ↗
NCT02525692
Dordaviprone (ONC201)

Phase 2 terminated small_molecule

Glioblastoma

CT.gov ↗
NCT02539823
CBD 400 mg

Phase 2 completed small_molecule

Opiate Addiction

CT.gov ↗
NCT02544750
GWP42003-P

Phase 3 completed small_molecule

Tuberous Sclerosis Complex

CT.gov ↗
NCT02544763
GWP42003-P

Phase 3 completed small_molecule

Tuberous Sclerosis Complex

CT.gov ↗
NCT02564952
GWP42003-P

Phase 3 completed small_molecule

Epilepsy

CT.gov ↗
NCT02565108
GWP42003-P 20 mg/kg/Day Dose

Phase 3 completed small_molecule

Epilepsy

CT.gov ↗
NCT02607891
GWP42003-P

Phase 3 completed small_molecule

Epilepsy

CT.gov ↗
NCT02607904
GWP42003-P

Phase 3 completed small_molecule

Epilepsy

CT.gov ↗
NCT02647190
Erwinia Chrysanthemi asparaginase

Phase 1 terminated small_molecule

Acute Lymphoblastic Leukemia (ALL)

CT.gov ↗
NCT02718755
Fludarabine

Phase 2 terminated small_molecule

Hematologic Malignancy

CT.gov ↗
NCT02806895
JZP-110

Phase 3 completed small_molecule

Obstructive Sleep Apnea

CT.gov ↗
NCT02806908
JZP-110

Phase 3 completed small_molecule

Narcolepsy

CT.gov ↗
NCT02851407
Defibrotide

Phase 3 completed small_molecule

Veno-occlusive Disease

CT.gov ↗
NCT02863991
ONC201

Phase 2 terminated small_molecule

Multiple Myeloma

CT.gov ↗
NCT02873338
Dociparstat sodium

Phase 2 completed small_molecule

Acute Myeloid Leukemia

CT.gov ↗
NCT02892123
ZW25 (Zanidatamab)

Phase 1 completed small_molecule

HER2-expressing Cancers

CT.gov ↗
NCT02953548
GWP42003-P

Phase 3 completed small_molecule

Infantile Spasms

CT.gov ↗
NCT02954887
GWP42003-P

Phase 3 completed small_molecule

Infantile Spasms

CT.gov ↗
NCT03030599
JZP-258

Phase 3 completed small_molecule

Narcolepsy With Cataplexy

CT.gov ↗
NCT03037203
JZP-110

Phase 2 completed small_molecule

Excessive Sleepiness

CT.gov ↗
NCT03101241
CX-8998

Phase 2 completed small_molecule

Essential Tremor

CT.gov ↗
NCT03202303
Cannabidivarin

Phase 2 active small_molecule

Autism Spectrum Disorder

CT.gov ↗
NCT03295396
Dordaviprone (ONC201)

Phase 2 terminated small_molecule

Glioma

CT.gov ↗
NCT03335267
CPX-351

Phase 2 completed small_molecule

Leukemia, Myeloid, Acute

CT.gov ↗
NCT03339297
Defibrotide

Phase 2 completed small_molecule

Graft-versus-host Disease

CT.gov ↗
NCT03339401
Brincidofovir

Phase 2 terminated small_molecule

Adenovirus

CT.gov ↗
NCT03393611
CPX-351

Phase 1 active small_molecule

Myelodysplastic Syndromes

CT.gov ↗
NCT03406702
CX-8998

Phase 2 completed small_molecule

Epilepsy

CT.gov ↗
NCT03416530
Dordaviprone (ONC201)

Phase 1 terminated small_molecule

Diffuse Intrinsic Pontine Glioma

CT.gov ↗
NCT03436953
CX-8998

Phase 2 terminated small_molecule

Parkinson's Disease

CT.gov ↗
NCT03485729
Dordaviprone (ONC201)

Phase 2 terminated small_molecule

Endometrial Cancer Recurrent

CT.gov ↗
NCT03532035
Brincidofovir

Phase 2 terminated small_molecule

Adenovirus

CT.gov ↗
NCT03533114
JZP-258

Phase 3 completed small_molecule

Idiopathic Hypersomnia

CT.gov ↗
NCT03555955
CPX-351

Phase 1 completed small_molecule

Hematologic Malignancy

CT.gov ↗
NCT03572764
CPX-351

Phase 1 active small_molecule

Myelodysplastic Syndromes

CT.gov ↗
NCT03575325
CPX-351

Phase 2 completed small_molecule

Lymphoid Leukemia

CT.gov ↗
NCT03825796
Enasidenib Mesylate

Phase 2 active small_molecule

Recurrent Acute Myeloid Leukemia

CT.gov ↗
NCT03848832
GWP42003-P

Phase 3 terminated small_molecule

Rett Syndrome

CT.gov ↗
NCT03849456
GWP42006

Phase 2 terminated small_molecule

Autism Spectrum Disorder

CT.gov ↗
NCT03865589
Ultrasound Elastography

Unknown active other

Bone Marrow Transplant Complications

CT.gov ↗
NCT03878199
Liposome-encapsulated Daunorubicin-Cytarabine

Phase 2 terminated small_molecule

Essential Thrombocythemia

CT.gov ↗
NCT03878927
CPX-351

Phase 2 completed small_molecule

Acute Myeloid Leukemia

CT.gov ↗
NCT03897127
Cytarabine

Phase 3 active small_molecule

Acute Myeloid Leukemia

CT.gov ↗
NCT03904251
Gemtuzumab Ozogamicin

Phase 1 terminated small_molecule

Acute Myelogenous Leukemia

CT.gov ↗
NCT03929666
ZW25 (Zanidatamab)

Phase 2 completed small_molecule

HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

CT.gov ↗
NCT03954106
Defibrotide

Phase 2 terminated small_molecule

DLBCL

CT.gov ↗
NCT04006925
Sodium Oxybate

Approved completed small_molecule

REM Sleep Behavior Disorder

CT.gov ↗
NCT04038437
CPX-351

Phase 2 completed small_molecule

Acute Myeloid Leukemia

CT.gov ↗
NCT04075747
CPX-351

Phase 2 completed small_molecule

Acute Myeloid Leukemia

CT.gov ↗
NCT04133480
GWP42003-P

Approved terminated small_molecule

Lennox-Gastaut Syndrome

CT.gov ↗
NCT04145531
IM JZP-458

Phase 3 completed small_molecule

Acute Lymphoblastic Leukemia

CT.gov ↗
NCT04195945
Liposome-encapsulated Daunorubicin-Cytarabine

Phase 2 active small_molecule

Acute Myeloid Leukemia

CT.gov ↗
NCT04203498
Nabiximols

Phase 3 terminated small_molecule

Multiple Sclerosis (MS)

CT.gov ↗
NCT04217278
Vyxeos

Phase 3 active small_molecule

Acute Myeloid Leukaemia

CT.gov ↗
NCT04224272
ZW25 (Zanidatamab)

Phase 2 completed small_molecule

HER2+/HR+ Breast Cancer

CT.gov ↗
NCT04231851
Glasdegib

Phase 2 active small_molecule

Acute Myelogenous Leukemia (AML) Due to Therapy

CT.gov ↗
NCT04252586
GWP42003-P

Phase 3 terminated small_molecule

Rett Syndrome

CT.gov ↗
NCT04269213
Liposome-encapsulated Daunorubicin-Cytarabine

Phase 2 active small_molecule

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome

CT.gov ↗
NCT04389840
Dociparstat sodium

Phase 3 terminated small_molecule

Coronavirus Disease 2019 (COVID-19)

CT.gov ↗
NCT04421456
GWP42003-P

Phase 2 terminated small_molecule

Schizophrenia

CT.gov ↗
NCT04425655
Fludarabine

Phase 2 terminated small_molecule

Acute Myeloid Leukemia, Adult

CT.gov ↗
NCT04447846
Cannabidiol

Phase 2 completed small_molecule

Sturge-Weber Syndrome

CT.gov ↗
NCT04485104
GWP42003-P

Phase 3 terminated small_molecule

Seizure in Participants With Tuberous Sclerosis Complex

CT.gov ↗
NCT04526288
Liposome-encapsulated Daunorubicin-Cytarabine

Phase 2 active small_molecule

Acute Myeloid Leukemia

CT.gov ↗
NCT04530604
Defibrotide

Phase 1 completed small_molecule

COVID

CT.gov ↗
NCT04541082
ONC206

Phase 1 active small_molecule

Central Nervous System Neoplasms

CT.gov ↗
NCT04571645
Dociparstat

Phase 3 terminated small_molecule

Acute Myeloid Leukemia

CT.gov ↗
NCT04592159
Nabiximols

Phase 3 terminated small_molecule

Post-Traumatic Stress Disorder

CT.gov ↗
NCT04602936
Solriamfetol

Approved active small_molecule

Binge Eating Disorder

CT.gov ↗
NCT04610658
Nivolumab

Phase 1 terminated small_molecule

Small-cell Lung Cancer

CT.gov ↗
NCT04652115
Defibrotide

Phase 2 active small_molecule

Covid19

CT.gov ↗
NCT04657666
Nabiximols

Phase 3 completed small_molecule

Spasticity in Participants With Multiple Sclerosis

CT.gov ↗
NCT04721691
Epidiolex 100 mg/mL Oral Solution

Phase 1 completed small_molecule

Electrical Status Epilepticus of Slow-Wave Sleep

CT.gov ↗
NCT04732065
ONC206

Phase 1 active small_molecule

Diffuse Midline Glioma (DMG)

CT.gov ↗
NCT04745026
GWP42003-P

Phase 2 completed small_molecule

Autism Spectrum Disorder

CT.gov ↗
NCT04794491
JZP-258

Approved completed small_molecule

Narcolepsy

CT.gov ↗
NCT04899050
Cannabidiol (Epidiolex)

Approved completed small_molecule

Study the Efficacy of Epidiolex for Typical Absence Seizures

CT.gov ↗
NCT04982354
CPX-351

Phase 2 completed small_molecule

Acute Myeloid Leukemia

CT.gov ↗
NCT04984278
Nabiximols

Phase 3 terminated small_molecule

Spasticity With Multiple Sclerosis

CT.gov ↗
NCT04990102
CPX-351

Phase 2 active small_molecule

Acute Myeloid Leukemia (AML) in Remission

CT.gov ↗
NCT05009992
ONC201

Phase 2 active small_molecule

Diffuse Intrinsic Pontine Glioma

CT.gov ↗
NCT05024552
Gilteritinib

Phase 1 active small_molecule

Acute Myeloid Leukemia With FLT3/ITD Mutation

CT.gov ↗
NCT05044819
Cannabidiol

Approved active small_molecule

Lennox Gastaut Syndrome

CT.gov ↗
NCT05091567
Atezolizumab

Phase 3 active small_molecule

Small-Cell Lung Cancer

CT.gov ↗
NCT05099666
Lurbinectedin

Phase 2 active small_molecule

Advanced Soft-tissue Sarcoma

CT.gov ↗
NCT05122650
JZP385

Phase 2 completed small_molecule

Essential Tremor

CT.gov ↗
NCT05126433
Lurbinectedin

Phase 2 terminated small_molecule

Advanced Solid Tumor

CT.gov ↗
NCT05178316
JZP150

Phase 2 completed small_molecule

Post Traumatic Stress Disorder

CT.gov ↗
NCT05229588
Lurbinectedin 4 MG Injection [Zepzelca]

Phase 2 completed small_molecule

Gastrointestinal Malignancies

CT.gov ↗
NCT05244239
Lurbinectedin

Phase 1 active small_molecule

Extensive Stage Lung Small Cell Carcinoma

CT.gov ↗
NCT05260528
Cytarabine and Idarubicin

Phase 2 active small_molecule

Acute Myeloid Leukemia

CT.gov ↗
NCT05288283
GWP42003-P

Phase 3 terminated small_molecule

Seizures Associated With EMAS

CT.gov ↗
NCT05391724
CMX001

Phase 1 completed small_molecule

Hepatic Impairment

CT.gov ↗
NCT05476939
Everolimus

Phase 3 active small_molecule

Diffuse Intrinsic Pontine Glioma

CT.gov ↗
NCT05542407
Atezolizumab

Phase 1 active small_molecule

Endometrial Cancer

CT.gov ↗
NCT05557045
JZP815

Phase 1 active small_molecule

Advanced Cancer

CT.gov ↗
NCT05558124
Vyxeos

Phase 1 active small_molecule

Acute Myeloid Leukemia

CT.gov ↗
NCT05574504
avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin

Phase 2 terminated small_molecule

Metastatic Cancer

CT.gov ↗
NCT05580562
Dordaviprone (ONC201)

Phase 3 active small_molecule

H3 K27M

CT.gov ↗
NCT05629702
Nabiximols

Phase 2 active small_molecule

Glioblastoma

CT.gov ↗
NCT05631327
JZP341

Phase 1 terminated small_molecule

Advanced Solid Tumor

CT.gov ↗
NCT05636111
Paclitaxel

Phase 1 active small_molecule

Ovarian Cancer

CT.gov ↗
NCT05642442
Placebo

Phase 2 completed small_molecule

Parkinson Disease

CT.gov ↗
NCT05651152
JZP441

Phase 1 completed small_molecule

Healthy Participants

CT.gov ↗
NCT05656248
CPX-351

Phase 2 active small_molecule

Myeloid Neoplasm

CT.gov ↗
NCT05720494
JZP441

Phase 1 completed small_molecule

Healthy Participants

CT.gov ↗
NCT05733390
JZP541

Phase 2 terminated small_molecule

Irritability Associated With Autism Spectrum Disorder

CT.gov ↗
NCT05734066
Lurbinectedin

Phase 2 active small_molecule

Refractory Ewing Sarcoma

CT.gov ↗
NCT05864846
Cannabidiol Oral Solution [Epidiolex]

Approved completed small_molecule

Tuberous Sclerosis Complex Associated Neuropsychiatric Disease

CT.gov ↗
NCT05869773
JZP258

Approved completed small_molecule

Narcolepsy

CT.gov ↗
NCT05875974
JZP258 (XYWAV)

Approved completed small_molecule

Idiopathic Hypersomnia

CT.gov ↗
NCT05918640
Lurbinectedin

Phase 2 active small_molecule

Ewing Sarcoma

CT.gov ↗
NCT05974293
Nabiximols

Phase 2 terminated small_molecule

NMO Spectrum Disorder

CT.gov ↗
NCT06012929
ONC201

Phase 2 terminated small_molecule

Meningioma

CT.gov ↗
NCT06043427
Paclitaxel

Phase 2 active small_molecule

Gastroesophageal Adenocarcinoma

CT.gov ↗
NCT06108050
JZP898

Phase 1 active small_molecule

Advanced Solid Tumor

CT.gov ↗
NCT06182410
Defibrotide

Phase 2 terminated small_molecule

Transplant-Associated Thrombotic Microangiopathy

CT.gov ↗
NCT06217536
Lurbinectedin

Phase 2 terminated small_molecule

Locally Advanced Soft Tissue Sarcoma

CT.gov ↗
NCT06261450
CBD Oral Solution (eCBD system Target)

Phase 2 active small_molecule

Fragile X Syndrome

CT.gov ↗
NCT06261502
CBD Oral Solution

Phase 2 active small_molecule

Fragile X Syndrome

CT.gov ↗
NCT06282575
Zanidatamab

Phase 3 active small_molecule

Biliary Tract Cancer

CT.gov ↗
NCT06435429
Zanidatamab

Phase 3 active small_molecule

Metastatic HER2-positive Breast Cancer

CT.gov ↗
NCT06695845
Zanidatamab

Phase 2 active small_molecule

Breast Cancer

CT.gov ↗
NCT06738368
Asparaginase Erwinia chrysanthemi

Phase 2 active small_molecule

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

CT.gov ↗
NCT06924827
Epidiolex 100 mg/mL Oral Solution

Approved active small_molecule

Dravet Syndrome (DS)

CT.gov ↗
NCT06961266
JZP441

Phase 1 terminated small_molecule

Narcolepsy

CT.gov ↗
NCT07102381
Zanidatamab

Phase 2 active small_molecule

HER2-positive Breast Cancer

CT.gov ↗
NCT07153055
Lurbinectedin

Phase 2 active small_molecule

Small Cell Lung Cancer ( SCLC )

CT.gov ↗
NCT07156435
Vyxeos 44 MG / 100 MG Liposome Injection

Phase 1 active small_molecule

Relapsed Pediatric AML

CT.gov ↗
NCT07176312
Zanidatamab

Phase 2 active small_molecule

Gastroesophageal Adenocarcinoma

CT.gov ↗
NCT07192068
Zanidatamab

Phase 2 active small_molecule

Non-Small Cell Lung Cancer

CT.gov ↗
NCT07233239
CBD-OS

Phase 1 active small_molecule

Focal Seizures

CT.gov ↗
NCT07278505
Cannabidiol

Phase 2 active small_molecule

Early Life Adversity

CT.gov ↗
NCT07282587
ONC206

Phase 2 active small_molecule

Advanced Pheochromocytoma and Paraganglioma

CT.gov ↗
NCT07377539
JZP047

Phase 1 active small_molecule

Healthy Participants

CT.gov ↗
NCT07434973
Cannabidiol (CBD)

Phase 3 active small_molecule

Clinical High Risk for Psychosis (CHR)

CT.gov ↗
NCT07459634
Lurbinectedin

Phase 2 active small_molecule

Extensive-stage Small-cell Lung Cancer

CT.gov ↗
NCT07533942
JZP3507

Phase 2 active small_molecule

Meningioma

CT.gov ↗